Edition:
United Kingdom

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.75USD
16 Feb 2018
Change (% chg)

$-0.02 (-1.13%)
Prev Close
$1.77
Open
$1.77
Day's High
$1.79
Day's Low
$1.72
Volume
11,293
Avg. Vol
28,420
52-wk High
$3.72
52-wk Low
$1.53

Chart for

About

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct... (more)

Overall

Beta: 0.40
Market Cap(Mil.): $65.20
Shares Outstanding(Mil.): 26.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Scynexis Inc Presents New In Vivo Data Highlighting The Potential Of Scy-078

* SCYNEXIS PRESENTS NEW IN VIVO DATA HIGHLIGHTING THE POTENTIAL OF SCY-078 USED IN COMBINATION FOR THE TREATMENT OF ASPERGILLUS INFECTIONS AT AAA 2018 Source text for Eikon: Further company coverage:

01 Feb 2018

BRIEF-Scynexis Provides Corporate And SCY-078 Pipeline Update

* SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​

04 Jan 2018

BRIEF-Scynexis reports third quarter 2017 financial results

* Scynexis reports third quarter 2017 financial results and provides company update

07 Nov 2017

BRIEF-Scynexis presents new data related to SCY-078​

* Scynexis Inc - ‍data demonstrates broad activity and potential clinical utility of SCY-078 against invasive candida and aspergillus infections Source text for Eikon: Further company coverage:

05 Oct 2017

Earnings vs. Estimates